Cargando…

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen

We aimed to investigate the long-term prognosis and prognostic factors of T-cell lymphoblastic lymphoma (T-LBL) patients who received dose-adjusted Berlin–Frankfurt–Münster (BFM)-90 regimen as first-line therapy in our center. A total of 145 T-LBL patients who underwent first-line dose-adjusted BFM-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Hui, Mi, Lan, Qi, Fei, Wang, Xing, Ye, Yingying, Li, Miaomiao, Wang, Dedao, Ding, Ning, Wang, Xiaogan, Song, Yuqin, Zhu, Jun, Xie, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037275/ https://www.ncbi.nlm.nih.gov/pubmed/35400665 http://dx.doi.org/10.18632/aging.204008

Ejemplares similares

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma
por: Xie, Yan, et al.
Publicado: (2015)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
por: Li, Chun, et al.
Publicado: (2020)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
por: Kroll, Mirko, et al.
Publicado: (2020)

The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma
por: Li, Jiao, et al.
Publicado: (2022)

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
por: Li, Miaomiao, et al.
Publicado: (2022)

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG
por: Dalle, Jean-Hugues, et al.
Publicado: (2020)

ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol
por: Wang, Yu, et al.
Publicado: (2018)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols
por: Ampatzidou, Mirella, et al.
Publicado: (2021)

miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment
por: Piatopoulou, Despina, et al.
Publicado: (2017)

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
por: Shi, Cunzhen, et al.
Publicado: (2018)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
por: Schieck, Maximilian, et al.
Publicado: (2020)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors
por: Gao, Hongye, et al.
Publicado: (2023)

Outcome of ALL With ALL-BFM-95 Protocol in Nepal
por: Sharma Poudyal, Bishesh, et al.
Publicado: (2023)

The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols
por: Ampatzidou, Mirella, et al.
Publicado: (2023)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Genome-Wide Mapping Reveals Complex Regulatory Activities of BfmR in Pseudomonas aeruginosa
por: Fan, Ke, et al.
Publicado: (2021)

The sensor kinase BfmS controls production of outer membrane vesicles in Acinetobacter baumannii
por: Kim, Se Yeon, et al.
Publicado: (2019)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group
por: Junk, Stefanie V., et al.
Publicado: (2023)

EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017)

A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China
por: Gao, Hongye, et al.
Publicado: (2022)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
por: Liu, Jiaxin, et al.
Publicado: (2023)

Second malignant neoplasms after treatment of 1487 children and adolescents with acute lymphoblastic leukemia—A population‐based analysis of the Austrian ALL‐BFM Study Group
por: Poyer, Fiona, et al.
Publicado: (2022)

The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii
por: Russo, Thomas A., et al.
Publicado: (2016)

PB1747: OUTCOME OF CHILDHOOD ALLTREATED WITH ALL BFM IC 2009 PROTOCOL
por: Çilsaat, Gizem, et al.
Publicado: (2023)

Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas
por: Ye, Yingying, et al.
Publicado: (2021)

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
por: Möricke, Anja, et al.
Publicado: (2023)

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial
por: Schweitzer, Jana, et al.
Publicado: (2015)

Desiccation tolerance in Acinetobacter baumannii is mediated by the two-component response regulator BfmR
por: Farrow, John M., et al.
Publicado: (2018)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
por: He, Yizi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iqphktuj70g6581hrj0sqjcvs4